Inhibitors of c-fms kinase
The invention is directed to compounds of Formula I:wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
Janssen Pharmaceutica NV
A A A C C A A A C C C A C A C C A A A A A A A A A A A A C A A
A61P A61P A61P C07D C07D A61P A61P A61P C07D C07D C07C A61P C07D A61P C07D C07D A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P C07D A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Mark Carl R. Renee Louise Sanath K. Shelley K. Kenneth Jinsheng
Wall Illig Desjarlais Meegalla Ballentine Wilson Chen